Radiation plus maintenance drugs for advanced pancreatic cancer
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests whether adding a focused radiation treatment (SBRT) to ongoing chemotherapy drugs works better than the drugs alone for pancreatic cancer that has stabilized or shrunk after initial treatment. The goal is to see if this combination approach helps patients live longer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18–70 years old
- Pancreatic cancer confirmed by biopsy or cell sample
- Completed at least 4 months of initial chemotherapy with stable or improved disease
- No prior radiation therapy to the pancreas
- Good overall health status (ECOG 0–2) with expected survival of at least 3 months
- Normal blood counts, liver, and kidney function within 2 weeks of enrollment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a new combination of super-precise radiation (guided SBRT), standard chemotherapy, and a newer immune medicine called Ivonescimab can slow or shrink pancreatic tumors that cannot be removed by surgery. The goal is to find a more effective treatment option.
This trial tests a very focused type of radiation (SBRT) for people with pancreatic cancer that hasn't spread to other organs but can't be removed with surgery. It may be an option if you are medically unable to have surgery or choose not to.
This trial tests a combination of targeted radiation and two oral drugs (defactinib and avutometinib) for people with advanced pancreatic cancer that hasn't spread to distant organs. It may be an option if you've already had at least 2 months of chemo and your cancer is still locally advanced or borderline resectable.
This trial tests whether combining targeted radiation with an at-home “tumor treating fields” device can better control locally advanced pancreatic cancer. It may help by attacking cancer cells in more than one way after prior chemotherapy.
This trial tests a new combination of treatments for pancreatic cancer that has spread. It adds a type of immunotherapy (called serplulimab) and targeted radiation (SBRT) to the usual chemotherapy, to see if it works better than chemotherapy alone in shrinking the cancer and helping you live longer.
This trial tests a combination of high-dose radiation (SBRT) and an immunotherapy drug called zimberelimab for people with locally advanced pancreatic cancer that can't be surgically removed. The goal is to see if the combination shrinks tumors or slows their growth better than standard care.
Hear when a new Pancreatic Cancer Non-resectable trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.